Idorsia has become the first drugmaker in the EU to claim approval for a drug for chronic insomnia in the dual orexin receptor antagonist class, ahead of rival drugs from Merck & Co and Eisai.

In November 2024, Idorsia outlined 270 positions worldwide that were at risk of redundancy to curb R&D activity. The insomnia ...

Daridorexant, Idorsia’s dual orexin receptor antagonist, shows consistent efficacy across both insomnia- and nocturia-related endpoints in a placebo-controlled study in patients with chronic ...

QUVIVIQ™ (daridorexant): Outstanding launch dynamic in France, and a strong performance in Germany accelerate sales in 2024 – Total Idorsia-led net sales of CHF 61 million in 2024. TRYVIO ...

February 28, 2024 Viatris forecasts strong 2024 sales on higher demand for branded drugs Drugmaker Viatris ... January 10, 2022 Idorsia's insomnia drug gets U.S. FDA approval Swiss drugmaker ...

Tryvio, an endothelin receptor antagonist (ERA), was approved in 2024 for the treatment of hypertension in combination with, other antihypertensive drugs ... According to Idorsia, the manufacturer ...

Welcome to the Idorsia Full Year 2024 Financial Results ... recent development in the pharmacological treatment of insomnia by European Sleep Research Society in its recent guidelines.

Idorsia Ltd (SIX: IDIA) today announced the publication of “A randomized cross-over trial of daridorexant for the treatment of chronic insomnia and nocturia” in the Journal of Sleep Research. The new ...

Idorsia believes that these non-GAAP financial ... In Germany, QUVIVIQ was launched in November 2022 and is the only sleep medication in Germany that can be prescribed for long-term treatment ...

Daridorexant, Idorsia’s dual orexin receptor antagonist, shows consistent efficacy across both insomnia- and nocturia-related endpoints in a placebo-controlled study in patients with chronic insomnia ...